V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010039 | 330004250 | null | 63.6 | Palliative (P) | 2015-04-18 | 2015-05-04 | Carboplatin AUC 2 - 5 | N | N | 330010712 | CARBOPLATIN |
| 330010040 | 330008328 | 1.42 | 51.3 | Curative (C) | 2017-06-02 | 2017-06-06 | Cetuximab 7 day (>Cycle 2) | 02 | Y | 330010739 | CETUXIMAB |
| 330010041 | 330008328 | null | 87.8 | Not known (9) | 2018-06-06 | 2018-06-23 | MAP | N | N | 330010739 | MAP |
| 330010042 | 330008329 | 1.67 | 75 | Palliative (P) | 2016-11-20 | 2017-01-07 | Docetaxel + Gemcitabine (prior RT) | N | N | 330010747 | DOCETAXEL + GEMCITABINE |
| 330010043 | 330004258 | 1.7 | 57.2 | Palliative (P) | null | 2013-08-08 | Cisplatin +Fluorouracil (2 wk) | Y | N | 330010803 | CISPLATIN + FLUOROURACIL |
| 330010044 | 330004259 | 1.79 | 66 | Palliative (P) | 2014-12-31 | 2015-04-05 | CETUXIMAB | 02 | N | 330010826 | CETUXIMAB |
| 330010045 | 330004259 | 1.69 | 47.9 | Curative (C) | 2017-02-10 | 2017-02-11 | Docetaxel + Gemcitabine (prior RT) | 02 | N | 330010826 | DOCETAXEL + GEMCITABINE |
| 330010046 | 330004259 | 0 | 52 | Palliative (P) | 2017-05-07 | 2017-07-03 | Etoposide + Ifosfamide (5 days) | 02 | N | 330010826 | ETOPOSIDE + IFOSFAMIDE |
| 330010047 | 330010518 | 1.55 | null | Curative (C) | null | 2016-08-11 | Rituximab | null | null | 330010843 | RITUXIMAB |
| 330010048 | 330004263 | 1.62 | 50 | Palliative (P) | 2014-09-07 | 2014-09-21 | Rituximab (INTRAVENOUS Maintenance) | N | null | 330010844 | RITUXIMAB |
| 330010049 | 330010519 | 0 | 64.2 | Neo-adjuvant (N) | 2018-02-26 | 2018-03-02 | Etoposide + Ifosfamide (3 days) | N | N | 330010845 | ETOPOSIDE + IFOSFAMIDE |
| 330010050 | 330013033 | 1.72 | 59.65 | Curative (C) | 2015-09-13 | 2016-03-03 | Rituximab (Maintenance) | 02 | N | 330010873 | RITUXIMAB |
| 330010051 | 330004265 | 1.6 | 58.2 | Curative (C) | null | 2019-02-14 | Carboplatin AUC 6 - 10 | 02 | N | 330010880 | CARBOPLATIN |
| 330010052 | 330004265 | 1.7 | 52 | Palliative (P) | null | 2018-02-12 | Etoposide + Ifosfamide (3 days) | N | N | 330010880 | ETOPOSIDE + IFOSFAMIDE |
| 330010053 | 330004269 | 1.62 | null | Neo-adjuvant (N) | 2016-02-19 | 2016-03-18 | PAM x 2 post-surgery (cycles 3&4) | null | null | 330010902 | MAP |
| 330010054 | 330008337 | 1.54 | 53 | Curative (C) | 2018-01-15 | 2018-01-17 | CETUXIMAB | 2 | N | 330010902 | CETUXIMAB |
| 330010055 | 330012414 | 1.67 | null | Neo-adjuvant (N) | 2017-05-12 | 2017-05-18 | Cisplatin +Fluorouracil (3 wk) | N | N | 330010903 | CISPLATIN + FLUOROURACIL |
| 330010056 | 330004276 | 0 | null | Palliative (P) | null | 2018-05-09 | ETOPOSIDE + IFOSFAMIDE | N | N | 330010929 | ETOPOSIDE + IFOSFAMIDE |
| 330010058 | 330004281 | 1.72 | 73.1 | Palliative (P) | 2015-08-10 | 2017-02-28 | DOCETAXEL + GEMCITABINE | 02 | N | 330010945 | DOCETAXEL + GEMCITABINE |
| 330010060 | 330004285 | 1.68 | 82.7 | null | 2015-10-08 | 2015-10-27 | Rituximab | N | Y | 330010968 | RITUXIMAB |
| 330010061 | 330010523 | 0 | 46.8 | Adjuvant (A) | 2016-08-01 | 2016-10-20 | Etoposide + Ifosfamide (3 days) | 2 | N | 330010974 | ETOPOSIDE + IFOSFAMIDE |
| 330010064 | 330004290 | 1.73 | 62.8 | Palliative (P) | 2017-09-05 | 2017-10-02 | MAP | 02 | N | 330011005 | MAP |
| 330010065 | 330004291 | 1.6 | 56.3 | Disease modification (D) | 2016-05-28 | 2016-05-29 | OST Euramos 1 Closed Trial - M | 2 | N | 330011005 | METHOTREXATE HIGH DOSE |
| 330010066 | 330004293 | 0 | 97 | Curative (C) | 2013-06-08 | 2013-07-06 | Etoposide + Ifosfamide (3 days) | N | N | 330011029 | ETOPOSIDE + IFOSFAMIDE |
| 330010067 | 330004298 | null | 63.6 | Palliative (P) | 2015-03-18 | 2015-04-01 | Etoposide + Ifosfamide (5 days) | N | N | 330011043 | ETOPOSIDE + IFOSFAMIDE |
| 330010068 | 330004300 | null | 54 | Curative (C) | 2017-04-05 | 2017-04-05 | Etoposide + Ifosfamide (5 days) | 2 | null | 330011064 | ETOPOSIDE + IFOSFAMIDE |
| 330010069 | 330004301 | 1.69 | 74 | Neo-adjuvant (N) | 2013-03-06 | 2013-07-22 | Docetaxel + Gemcitabine with GCSF | N | N | 330011097 | DOCETAXEL + GEMCITABINE |
| 330010070 | 330004306 | 1.8 | 72.4 | Curative (C) | 2016-04-18 | 2016-04-19 | CISPLATIN + FLUOROURACIL | 02 | N | 330011174 | CISPLATIN + FLUOROURACIL |
| 330010071 | 330004306 | 1.71 | 37.5 | Palliative (P) | 2017-03-13 | 2017-11-21 | Docetaxel + Gemcitabine (prior RT) | N | N | 330011174 | DOCETAXEL + GEMCITABINE |
| 330010072 | 330008357 | 1.67 | 72 | Disease modification (D) | 2013-12-07 | 2013-12-07 | Methotrexate High Dose (3g/m2) | N | N | 330011205 | METHOTREXATE HIGH DOSE |
| 330010073 | 330004310 | 0 | 57.8 | Curative (C) | 2015-09-27 | 2015-10-25 | ETOPOSIDE + IFOSFAMIDE | N | N | 330011211 | ETOPOSIDE + IFOSFAMIDE |
| 330010074 | 330004312 | 1.7 | 90.7 | Palliative (P) | 2017-11-06 | 2017-11-07 | Docetaxel + Gemcitabine (prior RT) | N | N | 330011224 | DOCETAXEL + GEMCITABINE |
| 330010075 | 330004314 | 1.77 | 84.9 | Curative (C) | 2017-05-26 | 2017-06-02 | MAP | 02 | N | 330011267 | MAP |
| 330010076 | 330004317 | 1.71 | 53 | Palliative (P) | 2016-01-09 | 2016-01-09 | Docetaxel+Gemcitabine (no prior RT) | 2 | Y | 330011269 | DOCETAXEL + GEMCITABINE |
| 330010077 | 330004318 | 1.75 | null | Neo-adjuvant (N) | 2018-02-16 | 2018-07-21 | PAM | 02 | N | 330011276 | MAP |
| 330010079 | 330008363 | 1.72 | 71.05 | null | 2017-05-03 | 2017-05-18 | Carboplatin AUC 6 - 10 | N | Y | 330011299 | CARBOPLATIN |
| 330010080 | 330004323 | 1.69 | 0 | null | 2017-11-21 | 2017-11-21 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330011311 | MAP |
| 330010081 | 330004326 | 1.6 | 57.9 | Palliative (P) | 2015-09-26 | 2015-09-28 | ETOPOSIDE + IFOSFAMIDE | N | Y | 330011340 | ETOPOSIDE + IFOSFAMIDE |
| 330010082 | 330004331 | 1.73 | 85.1 | Curative (C) | 2013-08-11 | 2013-10-01 | OST Euramos 1 Closed Trial - M | N | N | 330011341 | METHOTREXATE HIGH DOSE |
| 330010083 | 330011744 | 1.74 | 93.4 | Adjuvant (A) | 2013-11-19 | 2014-03-19 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330011354 | MAP |
| 330010084 | 330004332 | null | 37.4 | Palliative (P) | 2016-09-08 | 2016-09-27 | Cetuximab 7 day (Cycle 1) | 02 | N | 330011367 | CETUXIMAB |
| 330010085 | 330004333 | null | 65 | Curative (C) | 2017-09-11 | 2017-10-23 | Rituximab | 1 | N | 330011371 | RITUXIMAB |
| 330010086 | 330004335 | 0 | 58 | Palliative (P) | 2015-09-30 | 2015-11-04 | Carboplatin AUC 2 - 5 | N | Y | 330011387 | CARBOPLATIN |
| 330010087 | 330012420 | 1.68 | 69 | Palliative (P) | 2017-10-07 | 2018-04-09 | CARBOPLATIN | N | N | 330011387 | CARBOPLATIN |
| 330010088 | 330013333 | null | 58 | Curative (C) | null | 2017-06-25 | Methotrexate High Dose (3g/m2) | 2 | N | 330011441 | METHOTREXATE HIGH DOSE |
| 330010089 | 330008368 | 1.55 | null | Curative (C) | 2016-12-12 | 2016-12-26 | Docetaxel + Gemcitabine with GCSF | 02 | N | 330011449 | DOCETAXEL + GEMCITABINE |
| 330010090 | 330008368 | 1.68 | 61 | Palliative (P) | 2016-06-10 | 2016-06-16 | CETUXIMAB | N | N | 330011449 | CETUXIMAB |
| 330010091 | 330004338 | 1.46 | 42 | Palliative (P) | 2018-01-27 | 2018-01-27 | Docetaxel + Gemcitabine (prior RT) | N | N | 330011463 | DOCETAXEL + GEMCITABINE |
| 330010092 | 330004340 | 1.78 | 58.6 | Neo-adjuvant (N) | 2016-11-19 | 2016-11-19 | PAM x 2 post-surgery (cycles 3&4) | N | null | 330011479 | MAP |
| 330010093 | 330011747 | 1.81 | 58 | Adjuvant (A) | null | 2015-07-21 | PAM x 2 post-surgery (cycles 3&4) | null | null | 330011480 | MAP |